Bio-Technology General Corp. Enters Strategic Alliance for Four of Its Products Throughout the Middle East.

Business Editors

ISELIN, NJ--(BUSINESS WIRE)--March 28, 2000

Bio-Technology General Corp. (NASDAQ:BTGC) today announced a major, wide-ranging alliance with Al-Kindi Pharmaceutical Industries, a Jordanian company based in Amman, for the distribution of BTG's pharmaceutical products throughout the Arab world. Under the terms of the agreement, Al-Kindi has exclusive rights to market BTG's Bio-Hep-B(TM) recombinant hepatitis-B vaccine in Jordan, and BTG's Bio-Tropin(TM) recombinant human growth hormone for the treatment of short stature in children, Oxandrin(R) (oxandrolone, USP) for the treatment of involuntary weight loss, and BioLon(TM) sodium hyaluronate ophthalmic product in Jordan and most of the countries of the Middle East and North Africa. BTG will supply the products to Al-Kindi and Al-Kindi will register and market them in the licensed territory.

As part of its plans for bringing important pharmaceutical products to the Arab world, Al-Kindi has also previously obtained from a third party the right to purchase human insulin manufactured utilizing a process developed by BTG, and to formulate it in Jordan.

"We are very pleased indeed to have entered into this important relationship because it creates a new distribution channel for four of our products in many countries where they have not been available to date," stated Sim Fass, Chairman and CEO of BTG. "We believe that the commercial potential of these products in the licensed territory which covers a total population in excess of 300 million to be very significant. In addition, we look forward to the possible broadening of the scope of our strategic alliance with Al-Kindi to include both manufacturing of some of BTG's products as well as future research and clinical collaborations on new products that could be of further commercial benefit to both companies."

Bio-Technology General Corp., a leading biopharmaceutical company, develops, manufactures and markets genetically engineered and other products for human health care. The Company's products are marketed in over thirty countries worldwide.

Statements in this news release concerning the Company's business outlook or future economic performance, anticipated profitability, revenues, expenses or other financial items; and statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements" as that term is defined under the Federal Securities Laws. Forward-looking statements are subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to, changes and delays in product development plans and schedules, customer acceptance of new products, changes in pricing or other actions by competitors, patents owned by the Company and its competitors, and general economic conditions, as well as other risks detailed in the Company's filings with the Securities and Exchange Commission.